SOPHiA GENETICS Statistics
Total Valuation
SOPHiA GENETICS has a market cap or net worth of $336.84 million. The enterprise value is $329.57 million.
Important Dates
The next estimated earnings date is Tuesday, May 5, 2026, before market open.
| Earnings Date | May 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
SOPHiA GENETICS has 71.67 million shares outstanding. The number of shares has increased by 2.24% in one year.
| Current Share Class | 71.67M |
| Shares Outstanding | 71.67M |
| Shares Change (YoY) | +2.24% |
| Shares Change (QoQ) | +1.05% |
| Owned by Insiders (%) | 10.97% |
| Owned by Institutions (%) | 30.22% |
| Float | 51.31M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4.36 |
| Forward PS | 3.54 |
| PB Ratio | 6.83 |
| P/TBV Ratio | 29.93 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 4.27 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.96, with a Debt / Equity ratio of 1.34.
| Current Ratio | 1.96 |
| Quick Ratio | 1.72 |
| Debt / Equity | 1.34 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -15.58 |
Financial Efficiency
Return on equity (ROE) is -110.00% and return on invested capital (ROIC) is -37.46%.
| Return on Equity (ROE) | -110.00% |
| Return on Assets (ROA) | -27.85% |
| Return on Invested Capital (ROIC) | -37.46% |
| Return on Capital Employed (ROCE) | -63.05% |
| Weighted Average Cost of Capital (WACC) | 9.32% |
| Revenue Per Employee | $186,195 |
| Profits Per Employee | -$190,359 |
| Employee Count | 415 |
| Asset Turnover | 0.49 |
| Inventory Turnover | 4.12 |
Taxes
In the past 12 months, SOPHiA GENETICS has paid $1.51 million in taxes.
| Income Tax | 1.51M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +61.91% in the last 52 weeks. The beta is 1.04, so SOPHiA GENETICS's price volatility has been similar to the market average.
| Beta (5Y) | 1.04 |
| 52-Week Price Change | +61.91% |
| 50-Day Moving Average | 4.76 |
| 200-Day Moving Average | 4.27 |
| Relative Strength Index (RSI) | 45.74 |
| Average Volume (20 Days) | 92,966 |
Short Selling Information
The latest short interest is 254,959, so 0.36% of the outstanding shares have been sold short.
| Short Interest | 254,959 |
| Short Previous Month | 211,974 |
| Short % of Shares Out | 0.36% |
| Short % of Float | 0.50% |
| Short Ratio (days to cover) | 1.83 |
Income Statement
In the last 12 months, SOPHiA GENETICS had revenue of $77.27 million and -$79.00 million in losses. Loss per share was -$1.17.
| Revenue | 77.27M |
| Gross Profit | 52.08M |
| Operating Income | -70.93M |
| Pretax Income | -77.49M |
| Net Income | -79.00M |
| EBITDA | -69.17M |
| EBIT | -70.93M |
| Loss Per Share | -$1.17 |
Full Income StatementBalance Sheet
The company has $70.29 million in cash and $63.02 million in debt, with a net cash position of $7.27 million or $0.10 per share.
| Cash & Cash Equivalents | 70.29M |
| Total Debt | 63.02M |
| Net Cash | 7.27M |
| Net Cash Per Share | $0.10 |
| Equity (Book Value) | 47.15M |
| Book Value Per Share | 0.69 |
| Working Capital | 48.55M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$35.89 million and capital expenditures -$574,000, giving a free cash flow of -$36.47 million.
| Operating Cash Flow | -35.89M |
| Capital Expenditures | -574,000 |
| Depreciation & Amortization | 1.77M |
| Net Borrowing | 32.69M |
| Free Cash Flow | -36.47M |
| FCF Per Share | -$0.51 |
Full Cash Flow StatementMargins
Gross margin is 67.40%, with operating and profit margins of -91.80% and -102.24%.
| Gross Margin | 67.40% |
| Operating Margin | -91.80% |
| Pretax Margin | -100.28% |
| Profit Margin | -102.24% |
| EBITDA Margin | -89.51% |
| EBIT Margin | -91.80% |
| FCF Margin | n/a |
Dividends & Yields
SOPHiA GENETICS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.24% |
| Shareholder Yield | -2.24% |
| Earnings Yield | -23.45% |
| FCF Yield | -10.83% |
Analyst Forecast
The average price target for SOPHiA GENETICS is $7.00, which is 47.06% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $7.00 |
| Price Target Difference | 47.06% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | 25.34% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
SOPHiA GENETICS has an Altman Z-Score of -3.8 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -3.8 |
| Piotroski F-Score | 2 |
